Methyl rosmarinate is an allosteric inhibitor of SARS-cov-2 3 C L protease as a potential candidate against SARS-cov-2 infection
In conclusion, this paper provides the new ideas for the rapid discovery of active ingredients in TCM prescriptions formulas based on a specific target, and methyl rosmarinate has the potential to be developed as an antiviral therapeutic candidate against SARS-CoV-2 infection.PMID:38408645 | DOI:10.1016/j.antiviral.2024.105841 (Source: Antiviral Research)
Source: Antiviral Research - February 26, 2024 Category: Virology Authors: Hongtao Li Meng Sun Fuzhi Lei Jinfeng Liu Xixiang Chen Yaqi Li Ying Wang Jiani Lu Danmei Yu Yueqiu Gao Jianrong Xu Hongzhuan Chen Man Li Zhigang Yi Xiao He Lili Chen Source Type: research
An in vivo duck hepatitis B virus model recapitulates key aspects of nucleic acid polymer treatment outcomes in chronic hepatitis B patients
In conclusion, subcutaneous administration of NAPs in the DHBV duck model provides a useful tool for in vivo evaluation of NAPs. It recapitulates many aspects of this class of compound's efficacy in CHB patients, most notably the clear division between responders and non-responders.PMID:38401714 | DOI:10.1016/j.antiviral.2024.105835 (Source: Antiviral Research)
Source: Antiviral Research - February 24, 2024 Category: Virology Authors: Yannick Debing Hannah Vanrusselt Lars Degrauwe Daniel Apol ônio Silva de Oliveira Christopher Kinyanjui Kariuki Ebanja Joseph Ebwanga Shahbaz Bashir Wouter Merckx Santhosh Kumar Thatikonda Vivek Rajwanshi Vikrant Gohil Jin Hong Dieudonn é Buh Kum Abel A Source Type: research
An in vivo duck hepatitis B virus model recapitulates key aspects of nucleic acid polymer treatment outcomes in chronic hepatitis B patients
In conclusion, subcutaneous administration of NAPs in the DHBV duck model provides a useful tool for in vivo evaluation of NAPs. It recapitulates many aspects of this class of compound's efficacy in CHB patients, most notably the clear division between responders and non-responders.PMID:38401714 | DOI:10.1016/j.antiviral.2024.105835 (Source: Antiviral Research)
Source: Antiviral Research - February 24, 2024 Category: Virology Authors: Yannick Debing Hannah Vanrusselt Lars Degrauwe Daniel Apol ônio Silva de Oliveira Christopher Kinyanjui Kariuki Ebanja Joseph Ebwanga Shahbaz Bashir Wouter Merckx Santhosh Kumar Thatikonda Vivek Rajwanshi Vikrant Gohil Jin Hong Dieudonn é Buh Kum Abel A Source Type: research
The α-dystroglycan N-terminus is a broad-spectrum antiviral agent against SARS-CoV-2 and enveloped viruses
This study establishes soluble recombinant α-DGN as a broad-band, natural compound candidate therapeutic against enveloped viruses.PMID:38387750 | DOI:10.1016/j.antiviral.2024.105837 (Source: Antiviral Research)
Source: Antiviral Research - February 22, 2024 Category: Virology Authors: Maria Giulia Bigotti Katja Klein Esther S Gan Maria Anastasina Simon Andersson Olli Vapalahti Pekka Katajisto Maximilian Erdmann Andrew D Davidson Sarah J Butcher Ian Collinson Eng Eong Ooi Giuseppe Balistreri Andrea Brancaccio Yohei Yamauchi Source Type: research
The α-dystroglycan N-terminus is a broad-spectrum antiviral agent against SARS-CoV-2 and enveloped viruses
This study establishes soluble recombinant α-DGN as a broad-band, natural compound candidate therapeutic against enveloped viruses.PMID:38387750 | DOI:10.1016/j.antiviral.2024.105837 (Source: Antiviral Research)
Source: Antiviral Research - February 22, 2024 Category: Virology Authors: Maria Giulia Bigotti Katja Klein Esther S Gan Maria Anastasina Simon Andersson Olli Vapalahti Pekka Katajisto Maximilian Erdmann Andrew D Davidson Sarah J Butcher Ian Collinson Eng Eong Ooi Giuseppe Balistreri Andrea Brancaccio Yohei Yamauchi Source Type: research
The α-dystroglycan N-terminus is a broad-spectrum antiviral agent against SARS-CoV-2 and enveloped viruses
This study establishes soluble recombinant α-DGN as a broad-band, natural compound candidate therapeutic against enveloped viruses.PMID:38387750 | DOI:10.1016/j.antiviral.2024.105837 (Source: Antiviral Research)
Source: Antiviral Research - February 22, 2024 Category: Virology Authors: Maria Giulia Bigotti Katja Klein Esther S Gan Maria Anastasina Simon Andersson Olli Vapalahti Pekka Katajisto Maximilian Erdmann Andrew D Davidson Sarah J Butcher Ian Collinson Eng Eong Ooi Giuseppe Balistreri Andrea Brancaccio Yohei Yamauchi Source Type: research
Molnupiravir inhibits human norovirus and rotavirus replication in 3D human intestinal enteroids
Antiviral Res. 2024 Feb 17;223:105839. doi: 10.1016/j.antiviral.2024.105839. Online ahead of print.ABSTRACTHuman norovirus (HuNoV) and human rotavirus (HRV) are the leading causes of gastrointestinal diarrhea. There are no approved antivirals and rotavirus vaccines are insufficient to cease HRV associated mortality. Furthermore, treatment of chronically infected immunocompromised patients is limited to off-label compassionate use of repurposed antivirals with limited efficacy, highlighting the urgent need of potent and specific antivirals for HuNoV and HRV. Recently, a major breakthrough in the in vitro cultivation of HuNo...
Source: Antiviral Research - February 19, 2024 Category: Virology Authors: Nanci Santos-Ferreira Jana Van Dycke Winston Chiu Johan Neyts Jelle Matthijnssens Joana Rocha-Pereira Source Type: research
Mechanism of action of phthalazinone derivatives against rabies virus
Antiviral Res. 2024 Feb 17:105838. doi: 10.1016/j.antiviral.2024.105838. Online ahead of print.ABSTRACTRabies, a viral zoonosis, is responsible for almost 59,000 deaths each year, despite the existence of an effective post-exposure prophylaxis. Indeed, rabies causes acute encephalomyelitis, with a case-fatality rate of 100 % after the onset of neurological clinical signs. Therefore, the development of therapies to inhibit the rabies virus (RABV) is crucial. Here, we identified, from a 30,000 compound library screening, phthalazinone derivative compounds as potent inhibitors of RABV infection and more broadly of Lyssavirus ...
Source: Antiviral Research - February 19, 2024 Category: Virology Authors: Victoire Perraud Bart Vanderhoydonck Guillaume Bouvier Guilherme Dias de Melo Amuri Kilonda Mohamed Koukni Dirk Jochmans Sophie Rog ée Youcef Ben Khalifa Lauriane Kergoat Julien Lannoy Tina Van Buyten Nadia Izadi-Pruneyre Patrick Chaltin Johan Neyts Arna Source Type: research
Molnupiravir inhibits human norovirus and rotavirus replication in 3D human intestinal enteroids
Antiviral Res. 2024 Feb 17:105839. doi: 10.1016/j.antiviral.2024.105839. Online ahead of print.ABSTRACTHuman norovirus (HuNoV) and human rotavirus (HRV) are the leading causes of gastrointestinal diarrhea. There are no approved antivirals and rotavirus vaccines are insufficient to cease HRV associated mortality. Furthermore, treatment of chronically infected immunocompromised patients is limited to off-label compassionate use of repurposed antivirals with limited efficacy, highlighting the urgent need of potent and specific antivirals for HuNoV and HRV. Recently, a major breakthrough in the in vitro cultivation of HuNoV an...
Source: Antiviral Research - February 19, 2024 Category: Virology Authors: Nanci Santos-Ferreira Jana Van Dycke Winston Chiu Johan Neyts Jelle Matthijnssens Joana Rocha-Pereira Source Type: research
Mechanism of action of phthalazinone derivatives against rabies virus
Antiviral Res. 2024 Feb 17:105838. doi: 10.1016/j.antiviral.2024.105838. Online ahead of print.ABSTRACTRabies, a viral zoonosis, is responsible for almost 59,000 deaths each year, despite the existence of an effective post-exposure prophylaxis. Indeed, rabies causes acute encephalomyelitis, with a case-fatality rate of 100 % after the onset of neurological clinical signs. Therefore, the development of therapies to inhibit the rabies virus (RABV) is crucial. Here, we identified, from a 30,000 compound library screening, phthalazinone derivative compounds as potent inhibitors of RABV infection and more broadly of Lyssavirus ...
Source: Antiviral Research - February 19, 2024 Category: Virology Authors: Victoire Perraud Bart Vanderhoydonck Guillaume Bouvier Guilherme Dias de Melo Amuri Kilonda Mohamed Koukni Dirk Jochmans Sophie Rog ée Youcef Ben Khalifa Lauriane Kergoat Julien Lannoy Tina Van Buyten Nadia Izadi-Pruneyre Patrick Chaltin Johan Neyts Arna Source Type: research
Molnupiravir inhibits human norovirus and rotavirus replication in 3D human intestinal enteroids
Antiviral Res. 2024 Feb 17:105839. doi: 10.1016/j.antiviral.2024.105839. Online ahead of print.ABSTRACTHuman norovirus (HuNoV) and human rotavirus (HRV) are the leading causes of gastrointestinal diarrhea. There are no approved antivirals and rotavirus vaccines are insufficient to cease HRV associated mortality. Furthermore, treatment of chronically infected immunocompromised patients is limited to off-label compassionate use of repurposed antivirals with limited efficacy, highlighting the urgent need of potent and specific antivirals for HuNoV and HRV. Recently, a major breakthrough in the in vitro cultivation of HuNoV an...
Source: Antiviral Research - February 19, 2024 Category: Virology Authors: Nanci Santos-Ferreira Jana Van Dycke Winston Chiu Johan Neyts Jelle Matthijnssens Joana Rocha-Pereira Source Type: research
Mechanism of action of phthalazinone derivatives against rabies virus
Antiviral Res. 2024 Feb 17:105838. doi: 10.1016/j.antiviral.2024.105838. Online ahead of print.ABSTRACTRabies, a viral zoonosis, is responsible for almost 59,000 deaths each year, despite the existence of an effective post-exposure prophylaxis. Indeed, rabies causes acute encephalomyelitis, with a case-fatality rate of 100 % after the onset of neurological clinical signs. Therefore, the development of therapies to inhibit the rabies virus (RABV) is crucial. Here, we identified, from a 30,000 compound library screening, phthalazinone derivative compounds as potent inhibitors of RABV infection and more broadly of Lyssavirus ...
Source: Antiviral Research - February 19, 2024 Category: Virology Authors: Victoire Perraud Bart Vanderhoydonck Guillaume Bouvier Guilherme Dias de Melo Amuri Kilonda Mohamed Koukni Dirk Jochmans Sophie Rog ée Youcef Ben Khalifa Lauriane Kergoat Julien Lannoy Tina Van Buyten Nadia Izadi-Pruneyre Patrick Chaltin Johan Neyts Arna Source Type: research
Neutralizing antibodies to block viral entry and for identification of entry inhibitors
Antiviral Res. 2024 Feb 16:105834. doi: 10.1016/j.antiviral.2024.105834. Online ahead of print.ABSTRACTNeutralizing antibodies (NAbs) are naturally produced by our immune system to combat viral infections. Clinically, neutralizing antibodies with potent efficacy and high specificity have been extensively used to prevent and treat a wide variety of viral infections, including Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2), Human Immunodeficiency Virus (HIV), Dengue Virus (DENV) and Hepatitis B Virus (HBV). An overwhelmingly large subset of clinically effective NAbs operates by targeting viral envelope proteins...
Source: Antiviral Research - February 18, 2024 Category: Virology Authors: Ee Hong Tam Yu Peng Megan Xin Yan Cheah Chuan Yan Tianshu Xiao Source Type: research
Neutralizing antibodies to block viral entry and for identification of entry inhibitors
Antiviral Res. 2024 Feb 16:105834. doi: 10.1016/j.antiviral.2024.105834. Online ahead of print.ABSTRACTNeutralizing antibodies (NAbs) are naturally produced by our immune system to combat viral infections. Clinically, neutralizing antibodies with potent efficacy and high specificity have been extensively used to prevent and treat a wide variety of viral infections, including Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2), Human Immunodeficiency Virus (HIV), Dengue Virus (DENV) and Hepatitis B Virus (HBV). An overwhelmingly large subset of clinically effective NAbs operates by targeting viral envelope proteins...
Source: Antiviral Research - February 18, 2024 Category: Virology Authors: Ee Hong Tam Yu Peng Megan Xin Yan Cheah Chuan Yan Tianshu Xiao Source Type: research
Porcine interferon- α linked to the porcine IgG-Fc induces prolonged and broad-spectrum antiviral effects against the foot-and-mouth disease virus
Antiviral Res. 2024 Feb 13:105836. doi: 10.1016/j.antiviral.2024.105836. Online ahead of print.ABSTRACTFoot-and-mouth disease (FMD) is an economically important disease, and the FMD virus (FMDV) can spread rapidly in susceptible animals. FMD is usually controlled through vaccination. However, commercial FMD vaccines are only effective 4-7 days after vaccination. Furthermore, FMDV comprises seven serotypes and various topotypes, and these aspects should be considered when selecting a vaccine. Antiviral agents could provide rapid and broad protection against FMDV. Therefore, this study aimed to develop a consensus porcine in...
Source: Antiviral Research - February 15, 2024 Category: Virology Authors: Gyeongmin Lee Aro Kim Hyo Rin Kang Ji-Hyeon Hwang Jong-Hyeon Park Min Ja Lee Byounghan Kim Su-Mi Kim Source Type: research
